Clinical Trial: A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia

U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07908680) titled 'A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia' on Oct. 26.

Brief Summary: This study is designed to assess the safety and tolerability of the effects of XEP527, with particular emphasis on disease status and its compatibility with the standard of care in patients with stable schizophrenia.

Study Start Date: Nov. 04

Study Type: INTERVENTIONAL

Condition: Schizophrenia

Intervention: DRUG: XEP527

Participants will receive XEP527

DRUG: Placebo

Placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Novartis Pharmaceuticals

Disclaimer: Curated by HT Syndication....